Cash round sets up trial of InteRNA’s microRNA for cancer

Dutch biotech InteRNA Technologies has raised €18.5 million ($22 million) in second-round financing as it prepares to start clinical trials of its lead drug candidate INT-1B3 for solid tumo

Exicure lists on Nasdaq, raising $55m for cancer, neurology ...

Novartis’ severe aplastic anaemia drug fast-tracked by FDA

The FDA has accepted Novartis’ supplemental New Drug Application (sNDA) and granted Priority Review designation to Promacta (eltrombopag) in combination with standard immunosuppressive therapy (IST) for first-line treatment of severe aplastic anaemia (SAA), a rare and serious blood condition.